The Correlation Between the Astro Consensus Panel Definition of Biochemical Failure and Clinical Outcome for Patients with Prostate Cancer Treated with External Beam Irradiation

Horwitz, Eric M.; Vicini, Frank A.; Ziaja, Ellen L.; Dmuchowski, Carl; Stromberg, Jannifer S.; Martínez, Álvaro

doi:10.1016/s0360-3016(98)00078-9

Cited by 87 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17][18] In most, surrogate endpoints for disease progression are used based on various interpretations of PSA failure, PSA velocity, or time to PSA progression. [19][20][21][22][23][24] Nevertheless, the role of posttherapy PSA monitoring and its impact on clinical outcome remains controversial. 25 These data clearly demonstrate that both brachytherapy and surgery can prevent prostate cancer death, and the magnitude of the effect was similar for both cohorts.…”

Section: Discussionmentioning

confidence: 99%

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment

Tward

Lee

Pappas

et al. 2006

Cancer

View full text Add to dashboard Cite

BACKGROUND.The optimal treatment for men with early stage prostate cancer remains undefined. Survival of such patients after surgery, brachytherapy, or no definitive therapy was investigated specifically to determine the impact of age at diagnosis.METHODS.In all, 60,290 men diagnosed with organ‐confined, low and moderate grade prostate cancer between 1988 and 2002 were retrospectively identified from centers participating in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Prostate cancer‐specific mortality (PCSM) and any‐cause mortality (ACM) were determined. Outcomes for patients treated by brachytherapy, surgery, or receiving no definitive treatment were compared using the Wilcoxon test, stratified by T‐stage and grade, and using multivariate analysis.RESULTS.The median follow‐up time was 46 months (range, 0–189 months). For men under age 60 at diagnosis, PCSM at 10 years was 1.3%, 0.5%, and 3.7% for surgery, brachytherapy, and no definitive therapy, respectively. For men age 60 and older the PCSM was 3.8%, 5.3%, and 8.4%, respectively. On univariate and multivariate analysis, surgery and brachytherapy resulted in statistically equivalent PCSM and ACM, and both had a significantly lower PCSM and ACM versus no definitive therapy.CONCLUSIONS.A better survival was observed in men treated with a definitive therapy. The magnitude of the benefit on PCSM or ACM was similar for both definitive therapies irrespective of age. Cancer 2006. © 2006 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment

Tward

Lee

Pappas

et al. 2006

Cancer

View full text Add to dashboard Cite

show abstract

“…BF has been shown to precede distant metastasis and death (9,10). Earlier identification of BF is therefore paramount for effective salvage therapy.…”

Section: Discussionmentioning

confidence: 99%

How Can Men Destined for Biochemical Failure After Androgen Deprivation and Radiotherapy Be Identified Earlier?

D’Ambrosio

Ruth

Horwitz

et al. 2008

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose-The significance of prostate-specific antigen (PSA) increases during the recovery of androgen after androgen deprivation therapy (ADT) and radiotherapy for prostate cancer is not well understood. This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF). Methods and Materials-Between July 1992 and March 2004, 163 men with a Gleason score of 8-10 or initial PSA level >20 ng/mL, or Stage T3 prostate cancer were treated with radiotherapy (median dose, 76 Gy) and ADT and achieved an undetectable PSA level. The first detectable PSA level after the cessation of ADT was defined as the PSA sentinel rise (SR). A PSA-SR of >0.25, >0.5, >0.75, and >1.0 ng/mL was studied as predictors of BF (nadir plus 2 ng/mL). Cox proportional hazards models were used for univariate and multivariate analyses for BF adjusting for pretreatment differences in Gleason score, stage, PSA level (continuous), dose (continuous), and ADT duration (<12 vs. ≥12 months).Results-Of the 163 men, 41 had BF after therapy. The median time to BF was 25 months (range, 4-96). The 5-year BF rate stratified by a PSA-SR of ≤0.25 vs. >0.25 ng/mL was 28% vs. 43% (p = 0.02), ≤0.5 vs. >0.5 ng/mL was 30% vs. 56% (p = 0.0003), ≤0.75 vs. >0.75 ng/mL was 29% vs. 66% (p < 0.0001), and ≤1.0 vs. >1.0 ng/mL was 29% vs. 75% (p < 0.0001). All four PSA-SRs were independently predictive of BF on multivariate analysis. Conclusion-The PSA-SR predicts for BF. A PSA-SR of >0.5 ng/mL can be used for early identification of men at greater risk of BF.

show abstract

“…Both symptomatic and asymptomatic patients were eligible. Those without symptoms had three successive rises in serum PSA, in keeping with the American Society of Therapeutic Radiation Oncology guidelines (Horwitz et al, 1998). Previous hormone therapy was continued, with the exception of nonsteroidal antiandrogens (see below) and a change of hormonal therapy was not permitted.…”

Section: Eligibilitymentioning

confidence: 92%

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer

2004

View full text Add to dashboard Cite

The aim of this study was to examine the efficacy and toxicity of the epirubicin, carboplatin and 5-fluorouracil (ECarboF) regime in patients aged 70 or less with metastatic prostate cancer resistant to LHRH analogues. The majority of patients had previously received steroids as part of their systemic management and had progressive disease on steroids. In total, 80 patients were treated over a 6-year period, with objective response rates (PSA or radiological) of 45% and median time to relapse of 9.5 months. Median survival of the group was 9.2 months. In all, 32% of patients were alive at 12 months. Grade 3/4 neutropenia occurred in 34% of patients with an 8.7% rate of neutropenic sepsis. Grade 3/4 nonhaematological toxicity occurred in 28% of patients. For a substantial minority of patients with hormone refractory prostate cancer, combination chemotherapy can induce remission of significant duration. While similar responses have been documented for systemic cytotoxic -steroid combinations, the responses in this study are likely to reflect the activity of cytotoxic drugs alone.

show abstract

The Correlation Between the Astro Consensus Panel Definition of Biochemical Failure and Clinical Outcome for Patients with Prostate Cancer Treated with External Beam Irradiation

Cited by 87 publications

References 24 publications

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment

How Can Men Destined for Biochemical Failure After Androgen Deprivation and Radiotherapy Be Identified Earlier?

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer

Contact Info

Product

Resources

About